We recently published a list of 10 Stocks Insiders Spent The Most Money On Recently. In this article, we are going to take a ...
Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...
JMP Securities maintained a Market Outperform rating and a $41.00 price target for Exelixis (NASDAQ:EXEL) shares, aligning with the broader analyst consensus as five analysts have recently revised ...
Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic ...
Insider buying surged in February. Warren Buffett continues to build a stake in a media stock, and IPOs tempted some insiders as well.
The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...
with Sionna Therapeutics and Odyssey Therapeutics launching bids for IPOs following the steps of Maze Therapeutics and Metsera. As the federal reserve steps further into the easing cycle in 2025 ...
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) ("Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone ...
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated ...
This time, the company plans to sell $1 billion worth of stock and hit an $11.5 billion valuation in its planned IPO. That’s how the math works out for a proposed offering it announced Tuesday ...
Notably, Metsera (MTSR, NC), an emerging player in the obesity market, saw its stock soar by 47% on its first trading day. Merger and acquisition (M&A) activities in the biotech space were few but ...